European Investor
03 Apr 2026, 07:09
Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved Foundayo (orforglipron), the first oral GLP-1 treatment for weight loss that can be taken without food or water restrictions.
The once-daily pill is indicated for adults with obesity or overweight patients with related conditions and showed significant results in clinical trials, with participants losing up to 12.4% of body weight on the highest dose. The drug also demonstrated improvements in key cardiovascular risk markers, including blood pressure and cholesterol levels.
Foundayo will be available in the U.S. through LillyDirect starting in April, with broader distribution planned through retail pharmacies and telehealth providers. Pricing is expected to start as low as $25 per month for eligible insured patients.
The approval marks a major step in expanding access to GLP-1 therapies, offering a more convenient alternative to injectable treatments as demand for obesity medications continues to grow.
PRNewswire
The once-daily pill is indicated for adults with obesity or overweight patients with related conditions and showed significant results in clinical trials, with participants losing up to 12.4% of body weight on the highest dose. The drug also demonstrated improvements in key cardiovascular risk markers, including blood pressure and cholesterol levels.
Foundayo will be available in the U.S. through LillyDirect starting in April, with broader distribution planned through retail pharmacies and telehealth providers. Pricing is expected to start as low as $25 per month for eligible insured patients.
The approval marks a major step in expanding access to GLP-1 therapies, offering a more convenient alternative to injectable treatments as demand for obesity medications continues to grow.
PRNewswire